Literature DB >> 27696451

Fibrosis is not just fibrosis - basement membrane modelling and collagen metabolism differs between hepatitis B- and C-induced injury.

M J Nielsen1, M A Karsdal1,2, K Kazankov3, H Grønbaek3, A Krag4, D J Leeming1, D Schuppan5,6, J George7.   

Abstract

BACKGROUND: While morphological patterns differ, the molecular phenotype of liver fibrosis is considered a stereotypical response to chronic liver injury. However, with different cellular triggers and networks regulating fibrosis, the molecular responses of the injured liver may not be identical. AIM: To investigate whether differences in extracellular matrix (ECM) composition of the liver during fibrogenesis in two seemingly similar types of viral hepatitis could be reflected by differences in ECM turnover.
METHODS: Utilising a cross-sectional design, we measured specific ECM protein fragments in plasma from 197 chronic hepatitis B (CHB) patients and 403 chronic hepatitis C (CHC) patients matched for inflammation grade and fibrosis stage. Markers of matrix metalloprotease degraded type I, III, IV and VI collagen (C1M, C3M, C4M, C6M) and type III and IV collagen formation (Pro-C3, P4NP7S).
RESULTS: P4NP7S, C3M, C4M and C6M were significantly elevated in CHB compared to CHC. In contrast, Pro-C3 was significantly elevated in CHC compared to CHB. Pro-C3, C3M and C4M were increased in parallel with inflammation and fibrosis in both cohorts. C6M and P4NP7S were associated with inflammation and fibrosis only in CHC. Basement membrane collagen fragments P4NP7S and C4M were significantly higher in matched activity and fibrosis cohorts within CHB vs CHC.
CONCLUSION: The main parameters to determine extracellular matrix biomarker levels are inflammation, fibrosis, and type of viral insult. Compared to CHC, CHB appears to induce a higher basement membrane turnover. This suggests that there are aetiology-dependent molecular signatures in liver fibrosis that could have pathogenic and diagnostic implications.
© 2016 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27696451     DOI: 10.1111/apt.13819

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  9 in total

1.  LigaSure versus CUSA for parenchymal transection during laparoscopic hepatectomy in hepatocellular carcinoma patients with cirrhosis: a propensity score-matched analysis.

Authors:  Fei Liu; YongGang Wei; HongYu Li; WenTao Wang; TianFu Wen; Hong Wu; JiaYin Yang; MingQing Xu; Bo Li
Journal:  Surg Endosc       Date:  2017-11-09       Impact factor: 4.584

2.  Comprehensive assessment of ECM turnover using serum biomarkers establishes PBC as a high-turnover autoimmune liver disease.

Authors:  Mette Vesterhus; Mette Juul Nielsen; Johannes Roksund Hov; Francesca Saffioti; Tina Manon-Jensen; Diana Julie Leeming; Bjørn Moum; Kirsten Muri Boberg; Massimo Pinzani; Tom Hemming Karlsen; Morten Asser Karsdal; Douglas Thorburn
Journal:  JHEP Rep       Date:  2020-09-03

3.  PRO-C3, a Serological Marker of Fibrosis, During Childhood and Correlations With Fibrosis in Pediatric NAFLD.

Authors:  Catherine C Cohen; Eduardo Castillo-Leon; Alton B Farris; Shelley A Caltharp; Rebecca L Cleeton; Elizabeth M Sinclair; Diane E Shevell; Morten A Karsdal; Mette Juul Fisker Nielsen; Diana J Leeming; Miriam B Vos
Journal:  Hepatol Commun       Date:  2021-07-08

Review 4.  Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science.

Authors:  Yasser Fouad; Melissa Palmer; Minjun Chen; Arie Regev; Rajarshi Banerjee; Rob Myers; Robert Riccio; Richard Torstenson; Ramy Younes; Puneet S Arora; Henrik Landgren; Morten A Karsdal; Martin Blake; David A Shapiro; Hans-Juergen Gruss; Muhammad Y Sheikh; Dina Attia; Steven Bollipo; Alastair D Smith; Bradley Freilich; Robert G Gish; Detlef Schuppan
Journal:  J Clin Transl Hepatol       Date:  2021-10-22

5.  Collagen type IV remodelling gender-specifically predicts mortality in decompensated cirrhosis.

Authors:  Jennifer Lehmann; Michael Praktiknjo; Mette Juul Nielsen; Robert Schierwagen; Carsten Meyer; Daniel Thomas; Francesco Violi; Christian P Strassburg; Flemming Bendtsen; Søren Møller; Aleksander Krag; Morten Asser Karsdal; Diana Julie Leeming; Jonel Trebicka
Journal:  Liver Int       Date:  2019-03-07       Impact factor: 5.828

6.  Serum markers of type III and IV procollagen processing predict recurrence of fibrosis in liver transplanted patients.

Authors:  Mette Juul Nielsen; Ida Falk Villesen; Natasja Stæhr Gudmann; Diana Julie Leeming; Aleksander Krag; Morten Asser Karsdal; Tim Zimmermann; Detlef Schuppan
Journal:  Sci Rep       Date:  2019-10-16       Impact factor: 4.379

Review 7.  Molecular Crosstalk between the Hepatitis C Virus and the Extracellular Matrix in Liver Fibrogenesis and Early Carcinogenesis.

Authors:  Emma Reungoat; Boyan Grigorov; Fabien Zoulim; Eve-Isabelle Pécheur
Journal:  Cancers (Basel)       Date:  2021-05-09       Impact factor: 6.639

8.  Markers of Basement Membrane Remodeling Are Associated With Higher Mortality in Patients With Known Atherosclerosis.

Authors:  Signe Holm Nielsen; Christoffer Tengryd; Andreas Edsfeldt; Susanne Brix; Federica Genovese; Eva Bengtsson; Morten Karsdal; Diana J Leeming; Jan Nilsson; Isabel Goncalves
Journal:  J Am Heart Assoc       Date:  2018-11-06       Impact factor: 5.501

9.  PRO-C3 and ADAPT algorithm accurately identify patients with advanced fibrosis due to alcohol-related liver disease.

Authors:  Bjørn S Madsen; Maja Thiele; Sönke Detlefsen; Maria Kjaergaard; Linda S Møller; Jonel Trebicka; Mette J Nielsen; Natasja Staehr Gudmann; Diana J Leeming; Morten A Karsdal; Aleksander Krag
Journal:  Aliment Pharmacol Ther       Date:  2021-07-12       Impact factor: 9.524

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.